Dianthus Therapeutics Inc.
- Address
- 7 Times Square Floor 43rd Suite 4303
Sponsor Overview
Specializations
Immune-Mediated Neuromuscular Disorders
Dianthus Therapeutics Inc. focuses on clinical research in multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, and generalized myasthenia gravis, reflecting a strong interest in conditions where immune dysfunction disrupts nerve and muscle function.
- Multifocal motor neuropathy
- Chronic inflammatory demyelinating polyneuropathy
- Generalized myasthenia gravis
The sponsor’s trial portfolio is centered on disorders that affect strength, mobility, and neuromuscular transmission, with attention to patient populations experiencing chronic, relapsing immune-related disease.
Autoimmune Neurology
Its research activity extends across autoimmune neurological disease areas in which immune-mediated injury leads to progressive weakness, disability, and functional impairment.
- Peripheral nerve autoimmunity
- Neuromuscular junction disorders
- Chronic relapse prevention
Clinical interest is concentrated on therapeutic strategies for maintaining neurological function in disorders marked by ongoing immune activity and symptom recurrence.
Neuromuscular Therapeutics
The sponsored studies address treatment areas relevant to neuromuscular therapeutics, with emphasis on conditions that impair motor control, muscle activation, and peripheral nerve signaling.
- Motor weakness
- Muscle fatigability
- Peripheral neuropathy
This includes research across disorders where preserving strength and reducing clinical deterioration are central therapeutic goals.
Clinical Development in Rare Disease
The sponsor’s clinical research footprint includes rare disease programs in North America and multiple international settings, with a network of collaborating sites supporting studies in specialized neurological conditions.
- Specialist neurology sites
- International recruitment
- Patient access in rare disorders
Its therapeutic interest is concentrated in difficult-to-treat immune neuropathies and neuromuscular diseases that require focused clinical expertise.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial |  Belgium Bulgaria Croatia Denmark France Germany Italy Latvia Poland Romania Spain The Netherlands | Recruiting |
| Evaluation of DNTH103 Safety, Tolerability, and Efficacy in Adults with Multifocal Motor Neuropathy: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study | Denmark France Italy Poland Spain The Netherlands | Recruiting |
| Phase 2 Randomized, Blinded, Placebo-Controlled Study of DNTH103 in Adults with Generalized Myasthenia Gravis |  Czechia Denmark France Italy Norway Poland Spain Sweden The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 9 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 89 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases3 trials322 other sponsors
Partnered Research Centres
89 centres- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- Meibergdreef 9, 1105 AZ Amsterdam
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- 51 Av Du Mal De Lattre De Tassigny, 94000 Créteil
- Address
- Batiment Babinski Groupe 47 83, 47 Boulevard De L Hopital, 75013 Paris
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Dianthus Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.